Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1a/1b, Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK112 in Subjects with Advanced Solid Tumors
Akesobio Australia Pty Ltd
This trial will consist of a Dose Escalation phase, where the maximum tolerated dose of AK112 will be determined, and a Dose Expansion phase with patients that have specific tumour types. All patients eligible to participate in either part of this trial will receive intravenous administration of AK112 every 2 weeks.